Biochemical consequences of treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
D000293:Adolescent; D000328:Adult; D000818:Animals; D003070:Coformycin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D037102:Lectins; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009929:Organ Size / Q000187:drug effects; D015649:Pentostatin; D012263:Ribonucleosides / Q000627:therapeutic use*; D012265:Ribonucleotides / Q000378:metabolism*; D013154:Spleen / Q000187:drug effects
D037102:Lectins; D012263:Ribonucleosides; D012265:Ribonucleotides; D003070:Coformycin; D015649:Pentostatin